H. Zwickl, S. Traxler, W. Parzefall, B. Grasl-Kraupp, R.
Schulte-Hermann, C. Gerner. A novel technique to specifically analyse
the secretome of cells and tissues. Electrophoresis 26: 2779-2785,
2005 (IF 3,85).
C. Drucker, W. Parzefall, O. Teufelhofer, A. Ellinger, R.
Schulte-Hermann, B. Grasl-Kraupp. Non-parenchymal liver cells support
the growth advantage of (pre)malignant rat hepatocytes. Carcinogenesis
27: 152-161, 2006 (IF 5,366).
D. Macheiner, G. Heller, S. Kappel, C. Bichler, S. Stättner, B.
Ziegler, D. Kandioler, F. Wrba, R. Schulte-Hermann, S.
Zöchbauer-Müller, B. Grasl-Kraupp. NORE1B, a candidate
tumor suppressor, is epigenetically silenced in human hepatocellular
carcinoma. J of Hepatology, 45:81-89, 2006 (IF 6,073).
N. Rohr-Udilova, K. Stolze, S. Sagmeister, W. Parzefall, B. Marian,
H. Nohl, R. Schulte-Hermann, and B. Grasl-Kraupp. 2007. Cytotoxicity
of the novel spin trapping compound
5-ethoxycarbonyl-3,5-dimethyl-pyrroline N-oxide (3,5-EDPO) and its
derivatives. Bioorg. Med. Chem. Lett. 17: 5698-5703, 2007 (IF 2,662)
NV. Rohr-Udilova, K. Stolze, S. Sagmeister, H. Nohl, R.
Schulte-Hermann, B. Grasl-Kraupp. Lipid hydroperoxides from processed
dietary oils enhance growth of hepatocarcinoma cells. Mol Nutr Food
Res, 52: 352-359, 2008 (IF 3,308)
H. Fischer, N. Taylor, S. Allerstorfer, M. Grusch, G. Sonvilla, K.
Holzmann, U. Setinek, L. Elbling, H. Cantonati, B. Grasl-Kraupp, C.
Gauglhofer, B. Marian, M. Micksche, and W. Berger. Fibroblast growth
factor receptor-mediated signals contribute to the malignant phenotype
of non-small cell lung cancer cells: therapeutic implications and
synergism with epidermal growth factor receptor inhibition. Mol.
Cancer Ther. 7: 3408-3419, 2008 (IF 5,003).
S. Allerstorfer, G. Sonvilla, H. Fischer, S. Spiegl-Kreinecker, C.
Gauglhofer, U. Setinek, T. Czech, C. Marosi, J. Buchroithner, J.
Pichler, R. Silye, T. Mohr, K. Holzmann, B. Grasl-Kraupp, B. Marian,
M. Grusch, J. Fischer, M. Micksche, and W. Berger. FGF5 as an
oncogenic factor in human glioblastoma multiforme: autocrine and
paracrine activities. Oncogene 27: 4180-4190, 2008 (IF 7,216).
G. Sonvilla, S. Allerstorfer, S. Stättner, J. Karner, M.
Klimpfinger, H. Fischer, B. Grasl-Kraupp, K. Holzmann, W. Berger, F.
Wrba, B. Marian, and M. Grusch. FGF18 in colorectal tumour cells:
autocrine and paracrine effects. Carcinogenesis 29: 15-24, 2008 (IF
4,93).
S. Sagmeister, M. Eisenbauer, C. Pirker, T. Mohr, K. Holzmann, H.
Zwickl, C. Bichler, D. Kandioler, F. Wrba, W. Mikulits, C. Gerner, M.
Shehata, O. Majdic, B. Streubel, W. Berger, M. Micksche, K. Zatloukal,
R. Schulte-Hermann, B. Grasl-Kraupp. New cellular tools revela complex
epithelail mesenchymal interactions in hepatocarcinogenesis. British
Journal of Cancer 99:151-159, 2008a (IF 4,846).
H. K. Winter, H.K., V. A. Ehrlich, M. Grusch, A. Lackner, R.
Schulte-Hermann, B. Grasl-Kraupp, W. Mikulits, and S. Knasmüller. Use
of four new human-derived liver-cell lines for the detection of
genotoxic compounds in the single-cell gel electrophoresis (SCGE)
assay. Mutat.Res. 657:133-139, 2008 (IF 2,363).
S. Sagmeister, C. Drucker, A. Loset, M. Grusch, A. Daryabeigi, W.
Parzefall, N. Rohr-Udilova, C. Bichler, B. Semdsrod, D. Kandioler,
T. Grünberger, F. Wrba, R. Schulte-Hermann, and B. Grasl-Kraupp.
2008. HB-EGF is a paracrine growth stimulator for early tumor
prestages in inflammation-associated hepatocarcinogenesis. J
Hepatolology 49: 955-964, 2008b (IF 7,056).
D. Macheiner, C. Gauglhofer, C. Rodgarkia-Dara, M. Grusch, A.
Brachner, C. Bichler, D. Kandioler, H. Sutterlüty, W. Mikulits, R.
Schulte-Hermann, B. Grasl-Kraupp. NORE1B is a putative tumor
suppressor in hepatocarcinogenesis and may act via RASSF1A. Cancer
Research, 69:235-242, 2009 (IF 7,543).
G. Sonvilla, Allerstorfer S, Heinzle C, Stättner S, Karner J,
Klimpfinger M, Wrba F, Fischer H, Gauglhofer C, Spiegl-Kreinecker S,
Grasl-Kraupp B, Holzmann K, Grusch M, Berger W, Marian B. Fibroblast
growth factor receptor 3-IIIc mediates colorectal cancer growth and
migration. Br J Cancer. 102:1145-56, 2010 (IF 4,346).
O. Lorenz, Parzefall W, Kainzbauer E, Wimmer H, Grasl-Kraupp B,
Gerner C, Schulte-Hermann R. Proteomics reveals acute pro-inflammatory
and protective responses in rat Kupffer cells and hepatocytes after
chemical initiation of liver cancer and after LPS and IL-6. Proteomics
Clin. Appl., 3: 947-967, 2009 (IF 1,875).
G. Zulehner, Mikula M, Schneller D, van Zijl F, Huber H, Sieghart W,
Grasl-Kraupp B, Waldhör T, Peck-Radosavljevic M, Beug H, Mikulits W.
Nuclear beta-catenin induces an early liver progenitor phenotype in
hepatocellular carcinoma and promotes tumor recurrence. Am J Pathol.
176: 472-81, 2010 (IF 5,673).
F. Ferk, W. Huber, M. Filipič, J. Bichler, E. Haslinger, M. Mišík,
A.Nersesyan, B. Grasl-Kraupp, B. Zegura, S. Knasmüller. Xanthohumol,
a prenylated flavonoid contained in beer, prevents the induction of
preneoplastic lesions and DNA damage in liver and colon induced by the
heterocyclic aromatic amine amino-3-methyl-imidazo[4,5-f]quinoline
(IQ). Mutat Res. 10;691(1-2):17-22, 2010 (IF 2,552).
C. Gauglhofer, S. Sagmeister, Fischer C, Mohr T, Stättner S, Bichler
C, Kandioler D, Schulte-Hermann R, Holzmann K, Grusch M, Marian B,
Berger W, Grasl-Kraupp B. Upregulation of Fibroblast growth factor
8-subfamily in hepatocellular carcinoma may induce cell survival and
neoangiogenesis. Hepatology 53:854-64, 2011 (IF 10,840)
Heinzle C, Sutterlüty H, Grusch M, Grasl-Kraupp B, Berger W, Marian
B. Targeting fibroblast-growth-factor-receptor-dependent signaling for
cancer therapy. Expert Opin Ther Targets. 2011 Mar 7. [Epub ahead of
print]
Frost K, Seir K, Lackner A, Grusch M, Grasl-Kraupp B, Schulte-Hermann
R, Rodgarkia-Dara C. Inhibin/activin expression in human and rodent
liver: subunits α and βB as new players in human hepatocellular
carcinoma? Br J Cancer. 2011 Apr 12;104(8):1303-12. Epub 2011 Mar 15.
